Biomarker subanalysis of the phase III study of regorafenib vs placebo in TKI-refractory metastatic GIST

Researchers using a tool called BEAMing technology, which can detect cancer-driving gene mutations in patients’ blood samples, were able to identify oncogenic mutations associated with distinct responses to therapies used to treat patients with metastatic gastrointestinal stromal tumours (GIST), according to data presented at the AACR Annual Meeting 2013, held in Washington D.C., April 6-10. Read more here.